Lantheus Holdings: Radiopharmaceutical PYLARIFY Reaches $1 Billion in Annual Revenues! Two Major Acquisitions Were Announced!

Recession fears and a global trade war initiated by Donald Trump are pushing stock prices from one low to the next. The uncertainty factor in the USA is very high, and all sectors are showing red numbers. The "Healthcare" sector is currently holding up the best. We focus on Lantheus Holdings, a leader in the "Drug Manufacturers – Specialty & Generic" industry. Radiopharmaceuticals for oncology and precision diagnostics In 4 out of 5 cases, its contrast agent DEFINITY is used Revenue growth of 18.3% to $1.53 billion in 2024 ...